Patents Assigned to Biogen MA Inc.
  • Publication number: 20210130397
    Abstract: Provided herein, in some embodiments, are methods and compositions for purifying antibodies from cellular cultures using one or more thiol containing additives during a purification process, for example in a chromatographic purification process.
    Type: Application
    Filed: August 22, 2018
    Publication date: May 6, 2021
    Applicant: Biogen MA Inc.
    Inventors: Matthew Westoby, Greg Evangelist
  • Patent number: 10995130
    Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: May 4, 2021
    Assignee: Biogen MA Inc.
    Inventors: Kevin Maloney, Ke Gong, Roy Alston
  • Patent number: 10994003
    Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: May 4, 2021
    Assignee: Biogen MA Inc.
    Inventor: Vissia Viglietta
  • Patent number: 10968453
    Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: April 6, 2021
    Assignee: Biogen MA Inc.
    Inventor: Eric E. Swayze
  • Patent number: 10968181
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: April 6, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian Stuart Lucas, Edward Yin-Shiang Lin, Andrew George Capacci, Zhili Xin, Istvan Enyedy, TeYu Chen, John H. Jones, Kurt D. van Vloten
  • Patent number: 10961237
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: March 30, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • Patent number: 10959972
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: March 30, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Patent number: 10955422
    Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: March 23, 2021
    Assignee: Biogen MA, Inc.
    Inventors: Tatiana Plavina, John P. Carulli, Leonid Gorelik, Teresa Compton
  • Patent number: 10954303
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 23, 2021
    Assignee: BIOGEN MA INC.
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Patent number: 10947262
    Abstract: The invention herein describes a method to purify a target oligonucleotide using hydrophobic interaction chromatography (HIC). The method includes adding a salt to a mixture of the target oligonucleotide and product-related impurities, applying the diluted mixture, at a particular dynamic loading capacity, to the hydrophobic interaction chromatography resin (or hydrophobic adsorbent), washing the hydrophobic adsorbent with an aqueous salt solution, eluting the target oligonucleotide with a eluting solution, and collecting the eluent comprising the target oligonucleotide.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: March 16, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Robert S. Gronke, Ratnesh S. Joshi
  • Patent number: 10945951
    Abstract: Methods and apparatuses for dispersing a compound within the patient are described. In one embodiment, an effective amount of a compound may be present in the cerebrospinal fluid of a patient and a force may be applied to the torso of the patient sufficient to enhance the convection of the cerebrospinal fluid. In another embodiment, a bolus including a compound may be injected into the cerebrospinal fluid of a patient. The volume of the bolus may be between about 5% and 30% of the total volume of the cerebrospinal fluid of the patient.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: March 16, 2021
    Assignee: Biogen MA Inc.
    Inventor: Ajay Verma
  • Publication number: 20210071176
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
    Type: Application
    Filed: August 6, 2020
    Publication date: March 11, 2021
    Applicant: Biogen MA Inc.
    Inventors: Holly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • Patent number: 10925859
    Abstract: Compounds of formula I: and pharmaceutically acceptable salts, solvates, or hydrates thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts, solvates, or hydrates and the compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: February 23, 2021
    Assignee: Biogen MA Inc.
    Inventors: Vincent P. Sandanayaka, Sharon Shechter, Sharon Shacham, Dilara McCauley, Erkan Baloglu
  • Patent number: 10913782
    Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 9, 2021
    Assignee: Biogen MA Inc.
    Inventors: Hq Han, Xiaolan Zhou
  • Publication number: 20210032624
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject.
    Type: Application
    Filed: April 1, 2020
    Publication date: February 4, 2021
    Applicant: Biogen MA Inc.
    Inventors: Frank Rigo, C. Frank Bennett
  • Patent number: 10899753
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 26, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, J├╝rgen Schulz, Marta Nevalainen, Michael Dechantsreiter
  • Patent number: 10894040
    Abstract: The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: January 19, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin Guckian, Gnanasambandam Kumaravel
  • Patent number: 10875924
    Abstract: Antibodies and antibody fragments that specifically bind to glycoprotein IIb/IIIa (GPIIb/IIIa) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. In addition, methods of using the disclosed antibodies, antibody fragments, and chimeric molecules, e.g., to target agents to platelets and for the treatment or prevention of diseases or disorders are provided.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: December 29, 2020
    Assignee: Biogen MA Inc.
    Inventors: Joe Salas, Karl Hanf, Arjan van der Flier, Bradley R. Pearse
  • Publication number: 20200392447
    Abstract: Aspect of the disclosure relate to methods of assessing a bioreactor culture that involve determining a culture parameter of the manufacturing-scale bioreactor culture using a model that relates a Raman spectrum to the culture parameter. Related bioreactor system are also provided.
    Type: Application
    Filed: January 13, 2020
    Publication date: December 17, 2020
    Applicant: Biogen MA Inc.
    Inventors: Brandon Berry, Justin Moretto
  • Publication number: 20200376018
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: December 10, 2019
    Publication date: December 3, 2020
    Applicants: Biogen MA Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger